Abstract:This review article examines the decline in pancreatic β‐cell mass and function as central to the pathogenesis of type 1 and advanced type 2 diabetes. It discusses the potential for β‐cell regeneration in response to increased insulin demand and evaluates how various antidiabetic medications may affect this process. The therapeutic implications of these findings for the management and treatment of diabetes are explored, offering new insights into potential interventions. Nowadays, the focus of diabetes treatment has switched from lowering the glucose level to preserving glycemic homeostasis and slowing the disease progression. The main pathophysiology of both type 1 diabetes and long‐standing type 2 diabetes is pancreatic β‐cell mass loss and dysfunction. According to recent research, human pancreatic β‐cells possess the ability to proliferate in response to elevated insulin demands. It has been demonstrated that in insulin‐resistant conditions in humans, such as obesity or pregnancy, the β‐cell mass increases. This ability could be helpful in developing novel treatment approaches to restore a functional β‐cell mass. Treatment strategies aimed at boosting β‐cell function and mass may be a useful tool for managing diabetes mellitus and stopping its progression. This review outlines the processes of β‐cell failure and detail the many β‐cell abnormalities that manifest in people with diabetes mellitus. We also go over standard techniques for determining the mass and function of β‐cells. Lastly, we provide the therapeutic implications of utilizing antidiabetic drugs in controlling the mass and function of pancreatic β‐cells.

Β-Cell Apoptosis and Therapy Trend in Patients with Type 2 Diabetes

Research Progress on the Mechanism of Beta-Cell Apoptosis in Type 2 Diabetes Mellitus

Β-Cell Dynamics in Type 2 Diabetes and in Dietary and Exercise Interventions

Molecular Mechanism of Islet Β-Cell Functional Alternations During Type 2 Diabetes.

Review on Abnormal Apoptosis and Pathological Changes of Histiocyte Initiated by Diabetes Mellitus

Transcriptional Control of Pancreatic Β-Cell Identity and Plasticity During the Pathogenesis of Type 2 Diabetes.

Pancreatic -cell failure, clinical implications, and therapeutic strategies in type 2 diabetes

Pancreatic Beta-cell Dysfunction in Type 2 Diabetes

Β Cell Dedifferentiation: New Insight into the Pathogenesis of Β Cell Failure in Type 2 Diabetes——gone Backward Already...and Coming Back Again?

Pancreatic β-cell failure, clinical implications, and therapeutic strategies in type 2 diabetes

Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus

Pancreatic β‐cell apoptosis in type 2 diabetes is related to post‐translational modifications of p53 (Review)

Mitochondrial Apoptosis of Lymphocyte is Induced in Type 2 Diabetes

A Brief Review of the Mechanisms of β-Cell Dedifferentiation in Type 2 Diabetes

Type 2 diabetes: principles of pathogenesis and therapy

Cellular Signaling Pathways Regulating Β‑cell Proliferation As a Promising Therapeutic Target in the Treatment of Diabetes (Review)

Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes

Study on protective effect and mechanism of traditional Chinese medicine on islet βcell apoptosis in type 2 diabetes model

Progress of Immunotherapy Aiming at Preserving Residual Beta Cells of Islet

β cell aging and age-related diabetes

Β-Cell Neogenesis: A Rising Star to Rescue Diabetes Mellitus.